Fig. 3
From: Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10
Fig. 3 | Multiple Sclerosis and Demyelinating Disorders